

TABLE E-1 Summary of Results from Randomized Clinical Trials Comparing Warfarin with LMWH After Total Hip Arthroplasty*

Study	Overall Rate of Deep Venous Thrombosis†			Rate of Major Bleeding Episode†		
	Percentage	P Value	Symptomatic DVT Rate† (%)	Rate of Pulmonary Embolism† (%)	Percentage	P Value
Hull et al. ¹¹ (1993)						
Warfarin	10.7		0.4	NA	4.2	
Fragmin	24		1.0	NA	5.1	
Hamulyák et al. ¹² (1995)						
Warfarin	20		NA	NA	2.8	
Nadroparine	17		NA	NA	1.5	
RD Heparin Arthroplasty Group ¹³ (1994)						
Warfarin	11		NA	0	4.0	
RD heparin (twice daily)	7		NA	0	4.0	
Francis et al. ¹⁴ (1997)						
Warfarin	26‡		NA	NA	1.0	0.03‡
Dalteparin	15	0.006‡	NA	NA	4.0‡	
Lassen et al. ²³ (2002)						
Enoxaparin	9‡		0.1	0.2	<1	
Fondaparinux	4	<0.0001‡	0.3	0.2	<1	
Turpie et al. ²⁴ (2002)						
Enoxaparin	8†		0	0.1	0.3	
Fondaparinux	6	0.047‡	0.4	0.4	0.2	

*Modified from: Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005 Sep;87(9):2097-112. †Percentages are based on the number of patients affected divided by the total number. P values are given if they were reported. NA = not available. ‡Results that had a significant difference.

TABLE E-2 Summary of Results from Randomized Clinical Trials Comparing Warfarin with LMWH After Total Knee Arthroplasty*

Study	Overall Rate of Deep Venous Thrombosis†		Rate of Symptomatic Deep Venous Thrombosis†	Rate of Pulmonary Embolism†		Rate of Major Bleeding Episode†	
	Percentage	P Value	Percentage	Percentage	P Value	Percentage	P Value
Hull et al. ¹¹ (1993)							
Warfarin	54.9		NA	0		2.4	
Logiparin	45.0		NA	0		4.4	
RD Heparin Arthroplasty Group ¹³ (1994)							
Warfarin	41.0‡		NA	1		NA	
RD heparin	25.0	0.004‡	NA	0		NA	
Heit et al. ¹⁷ (1997)							
Warfarin	38.0‡		NA	0.04		4.4	0.08
Ardeparin	27.0	0.019‡	NA	0		7.9	
Leclerc et al. ¹⁶ (1996)							
Warfarin	51.7‡		NA	0.9		1.8	>0.2
Enoxaparin	36.9	0.003‡	NA	0.3	>0.2	2.1	
Fitzgerald et al. ¹⁸ (2001)							
Warfarin	45.5§		NA	0.6		2.3	0.17
Enoxaparin	25.4	0.0001§	NA	0		5.2	
Bauer et al. ²⁵ (2001)							
Enoxaparin	27.1‡		0.8	0.8		0‡	
Fondaparinux	12.5	<0.001‡	0.6	0.2		1.7	0.006‡

*Modified from: Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005 Sep;87(9):2097-112. †Percentages are based on the number of patients affected divided by the total number. P values are given if they were reported. NA = not available. ‡Results that had a significant difference. §Results reported had a significant difference but represented the rate of venous thromboembolic disease, which consisted of DVT and PE.